Further in vitro and in vivo validations revealed that high MKRN1 expression was closely correlated with Oxa-resistance of CRC cells, and clinical data also confirmed that MKRN1 expression levels negatively correlated with patient response to Oxa treatment. This evidence concerns the gene MKRN1 and colorectal carcinoma.